Parathyroid hormone in the recovery from hip fractures: a pilot study

INTERVENTION: Intervention: tereparatide (Forsteo®) 20 µg/day injections Comparator: standard care Total duration of treatment: 6 weeks Total duration of follow up: 6 months Subjects participating in nested qualitative study will be followed for 12 months. CONDITION: Hip fractures ; Injury, Occupational Diseases, Poisoning ; Hip fracture PRIMARY OUTCOME: Participant numbers including recruitment rate, drop out rate, mortality rates, measured at baseline, 6 weeks, 3 months, 6 months (+12 months for qualitative sub group) SECONDARY OUTCOME: 1. Short Physical Performance Battery, measured at 6 weeks, 3 months (+6 months and 12 months for qualitative sub study); 2. 36‐item Short Form Health Survey (SF36), measured at 6 weeks, 3 months, 6 months by phone (+ 12 months for qualitative sub study); 3. EQ5D, measured at 6 weeks, 3 months, 6 months by phone (+ 12 months for qualitative sub study); 4. Visual Analog Scale (VAS) pain, measured at 6 weeks, 3 months, 6 months by phone (+ 12 months for qualitative sub study); 5. Compliance rates, measured at 6 weeks INCLUSION CRITERIA: Patients admitted to Frenchay Hospital with diagnosis of a pertrochanteric femoral fracture over the age of 60 years (either sex)